Information Provided By:
Fly News Breaks for February 11, 2016
INCY
Feb 11, 2016 | 09:43 EDT
Jefferies analyst Brian Abrahams calls the complete Jakafi discontinuation in solid tumors a "negative headline" but points out he believes it was already written out of expectations following last month's trial failure. Abrahams thinks Incyte's 2016 Jakafi guidance leaves room for upside. He has a Buy rating on the stock with a $106 price target.
News For INCY From the Last 2 Days
INCY
INCY
INCY
INCY
INCY
INCY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.